People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019
Feature | Cath Lab

October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with ...

Home October 03, 2019
Home
News | Heart Failure

October 3, 2019 – The three-year results from the COAPT Trial demonstrated that reducing severe secondary mitral ...

Home October 03, 2019
Home
News | Heart Valve Technology

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate neo ...

Home October 02, 2019
Home
Videos | University of Colorado Hospital

Interview with John Carroll, M.D., director of interventional cardiology, Robert Quaife, M.D., director of advanced ...

Home October 02, 2019
Home
News | Heart Valve Technology

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and one ...

Home October 02, 2019
Home
News | Cath Lab | Dave Fornell, Editor

October 2, 2019 — Democratic presidential candidate Sen. Bernie Sanders (D-VT) was hospitalized with chest pain on Oct ...

Home October 02, 2019
Home
News | Intra-Vascular Ultrasound (IVUS)

October 2, 2019 — Philips Healthcare is utilizing Level Ex’s video game app design expertise to train interventional ...

Home October 02, 2019
Home
360 Photos | 360 View Photos

This 360 degree view shows staff at the University of Colorado Heart and Vascular Center performing live transesophageal ...

Home October 02, 2019
Home
Blog | University of Colorado Hospital

I recently had the opportunity to conduct an onsite visit to the University of Colorado Hospital Heart and Vascular ...

Home October 02, 2019
Home
Comparison of a STEMI coronary artery blockage pre- and post-PCI for a patient who had a 9-minute door-to-balloon time at a rural hospital that implemented a pre-hospital STEMI protocol. This article was submitted by UH Portage Medical Center about how they set up their program.
Feature | Dave Fornell, Editor

October 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home October 01, 2019
Home
Khaldoon Alaswad, M.D., right, director, cardiac catheterization lab, during a complex CTO procedure at Henry Ford Hospital.
Feature | Henry Ford Hospital | Dave Fornell, Editor

Henry Ford Hospital thought leaders regularly speak at the cardiology conferences about new research and technology ...

Home October 01, 2019
Home
Videos | Heart Valve Technology

Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of the ...

Home September 30, 2019
Home
News | Stents Drug Eluting

The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

Home September 30, 2019
Home
News | Stents Drug Eluting

A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT.

Home September 30, 2019
Home
Videos | Structural Heart

A discussion with William O’Neill, M.D., director of the Henry Ford structural heart program, Ruth Fisher, MBA, vice ...

Home September 30, 2019
Home
Subscribe Now